{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:36:15Z","timestamp":1775291775756,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,31]],"date-time":"2015-01-31T00:00:00Z","timestamp":1422662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s11096-015-0070-y","type":"journal-article","created":{"date-parts":[[2015,1,30]],"date-time":"2015-01-30T04:37:30Z","timestamp":1422592650000},"page":"365-372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital"],"prefix":"10.1007","volume":"37","author":[{"given":"Lorena Rocha","family":"Ayres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00edlia Silveira","family":"de Almeida Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thais","family":"de Oliveira Gozzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edson Zangiacomi","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Queir\u00f3z","family":"Ungari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurandyr Moreira","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo R\u00e9gis Leira","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,31]]},"reference":[{"key":"70_CR1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893\u2013917.","journal-title":"Int J Cancer"},{"key":"70_CR2","volume-title":"Estimativa 2012: Incid\u00eancia de C\u00e2ncer no Brasil","author":"Instituto Nacional do C\u00e2ncer","year":"2011","unstructured":"Instituto Nacional do C\u00e2ncer. Estimativa 2012: Incid\u00eancia de C\u00e2ncer no Brasil. Rio de Janeiro: Minist\u00e9rio da Sa\u00fade; 2011."},{"key":"70_CR3","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S1470-2045(11)70323-0","volume":"13","author":"BL Lee","year":"2012","unstructured":"Lee BL, Liedke PE, Barrios CH, et al. Breast cancer in Brazil: present status and future goals. Lancet Oncol. 2012;13:e95\u2013102.","journal-title":"Lancet Oncol"},{"key":"70_CR4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2\/neu oncogene. Science. 1987;235:177\u201382.","journal-title":"Science"},{"key":"70_CR5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:789\u201392.","journal-title":"N Engl J Med"},{"key":"70_CR6","first-page":"289","volume":"3","author":"CG Murphy","year":"2009","unstructured":"Murphy CG, Modi S. HER2 breast cancer therapies: a review. Biologics. 2009;3:289\u2013301.","journal-title":"Biologics"},{"issue":"Suppl 4","key":"70_CR7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0959-8049(01)00230-1","volume":"37","author":"Y Yarden","year":"2001","unstructured":"Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3\u20138.","journal-title":"Eur J Cancer"},{"key":"70_CR8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118\u201345.","journal-title":"J Clin Oncol"},{"key":"70_CR9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320\u201368.","journal-title":"Oncologist"},{"key":"70_CR10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659\u201372.","journal-title":"N Engl J Med"},{"key":"70_CR11","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","volume":"28","author":"M Procter","year":"2010","unstructured":"Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28:3422\u20138.","journal-title":"J Clin Oncol"},{"key":"70_CR12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11523-009-0112-2","volume":"4","author":"E Azambuja de","year":"2009","unstructured":"de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol. 2009;4:77\u201388.","journal-title":"Target Oncol"},{"key":"70_CR13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cardfail.2009.04.011","volume":"15","author":"M Guglin","year":"2009","unstructured":"Guglin M, Hartlage G, Reynolds C, et al. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail. 2009;15:651\u20137.","journal-title":"J Card Fail"},{"key":"70_CR14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-008-0260-6","volume":"117","author":"D Wadhwa","year":"2009","unstructured":"Wadhwa D, Fallah-Rad N, Grenier D, et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat. 2009;117:357\u201364.","journal-title":"Breast Cancer Res Treat"},{"key":"70_CR15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","volume":"18","author":"L Tarantini","year":"2012","unstructured":"Tarantini L, Cioffi G, Gori S, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail. 2012;18:113\u201319.","journal-title":"J Card Fail"},{"key":"70_CR16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/heartjnl-2012-303151","volume":"99","author":"A Farolfi","year":"2013","unstructured":"Farolfi A, Melegari E, Aquilina M, et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart. 2013;99:634\u20139.","journal-title":"Heart"},{"key":"70_CR17","unstructured":"Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo (HCFMRP\/USP). http:\/\/www.hcrp.fmrp.usp.br\/sitehc\/informacao.aspx?id=5&ref=1&refV=1 . Last accessed 26 May 2013."},{"key":"70_CR18","unstructured":"Brasil. Portaria n\u00ba 741 de 19 de dezembro de 2005. http:\/\/portal.anvisa.gov.br\/wps\/wcm\/connect\/3092aa80474594909c3fdc3fbc4c6735\/PORTARIA+N%C2%BA+741-2005.pdf?MOD=AJPERES . Last accessed 26 May 2013."},{"key":"70_CR19","unstructured":"Minist\u00e9rio da Sa\u00fade. http:\/\/portal.saude.gov.br\/portal\/arquivos\/pdf\/Trastuzumabe_caavancado_final.pdf . Last accessed 26 May 2013."},{"key":"70_CR20","volume-title":"Logistic regression using the SAS system: theory and application","author":"PD Allison","year":"2001","unstructured":"Allison PD. Logistic regression using the SAS system: theory and application. Cary: SAS Books; 2001."},{"key":"70_CR21","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience. J Clin Oncol. 2006;24:4107\u201315.","journal-title":"J Clin Oncol"},{"key":"70_CR22","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"1995","unstructured":"Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 1995;353:1673\u201384.","journal-title":"N Engl J Med"},{"key":"70_CR23","author":"K Aogi","year":"2012","unstructured":"Aogi K, Saeki T, Nakamura S, et al. A multicenter, phase II study of epirubicin\/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). Int J Clin Oncol. 2012;. doi: 10.1007\/s10147-012-0437-1 .","journal-title":"Int J Clin Oncol"},{"key":"70_CR24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trial. Lancet. 2012;379:432\u201344.","journal-title":"Lancet"},{"key":"70_CR25","doi-asserted-by":"crossref","unstructured":"Roca-Alonso L, Pellegrino L, Castellano L, et al. Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms? Cardiology 2012;122:253\u201359.","DOI":"10.1159\/000339858"},{"key":"70_CR26","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","volume":"339","author":"PK Singal","year":"1998","unstructured":"Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900\u20135.","journal-title":"N Engl J Med"},{"key":"70_CR27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11523-011-0203-8","volume":"6","author":"S Cosimo Di","year":"2011","unstructured":"Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol. 2011;6:189\u201395.","journal-title":"Target Oncol"},{"key":"70_CR28","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820\u20136.","journal-title":"J Clin Oncol"},{"key":"70_CR29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","volume":"37","author":"T Chen","year":"2011","unstructured":"Chen T, Xu T, Li Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev. 2011;37:312\u201320.","journal-title":"Cancer Treat Rev"},{"key":"70_CR30","doi-asserted-by":"crossref","unstructured":"Dent S, Hopkins S, Graham N. The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: an observational study. Cardiol Res Pract. 2012;2012:135819. doi: 10.1155\/2012\/135819 .","DOI":"10.1155\/2012\/135819"},{"key":"70_CR31","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdr348","volume":"23","author":"C Serrano","year":"2012","unstructured":"Serrano C, Cort\u00e9s J, De Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2012;23:897\u2013902.","journal-title":"Ann Oncol"},{"key":"70_CR32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/clpt.2011.74","volume":"90","author":"JG Hasselt van","year":"2011","unstructured":"van Hasselt JG, Boekhout AH, Beijnen JH, et al. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity. Clin Pharmacol Ther. 2011;90:126\u201332.","journal-title":"Clin Pharmacol Ther"},{"key":"70_CR33","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/sj.bjc.6603340","volume":"95","author":"KF Fox","year":"2006","unstructured":"Fox KF. The evaluation of left ventricular function for patients being considered for, or receiving trastuzumab (Herceptin) therapy. Br J Cancer. 2006;95:1454.","journal-title":"Br J Cancer"},{"key":"70_CR34","unstructured":"Minist\u00e9rio da Sa\u00fade. http:\/\/portal.saude.gov.br\/portal\/arquivos\/pdf\/Relatorio_Trastuzumabe_ca_inicial.pdf . Last accessed 26 May 2013."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0070-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-015-0070-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0070-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:54:49Z","timestamp":1559368489000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-015-0070-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,31]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["70"],"URL":"https:\/\/doi.org\/10.1007\/s11096-015-0070-y","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,31]]}}}